Purpose: Promising new therapeutic options for follicular lymphoma (FL) include fludarabine plus mitoxantrone (FM) and the mouse/human anti-CD20 antibody, rituximab. We performed a randomized comparative trial of FM with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) front-line chemotherapy with and without sequential rituximab. Patients and Methods: All previously untreated CD20+ FL patients presenting in 15 Italian cooperative institutions from October 1999 were randomly allocated to FM or CHOP. Following clinical or molecular restaging, patients in complete remission (CR) with bcl-2/lgH negativity (CR-) received no further treatment; those in CR with bcl-2/lgH positivity (CR+) received rituximab, as did those in partial remission (PR) with bcl-2/lgH negativity (PR-) or positivity (PR+); nonresponders (NR subgroup) were off study. Results: After chemotherapy, the FM arm achieved higher rates of CR (68% [49 of 72 patients] v 42% [29 of 68 patients]; P = .003) and CR- (39% [28 of 72 patients] v 13 of 68 patients [19%]; P = .001). Rituximab elicited CR - in 55 of 95 treated patients (58%). The final CR- rate was higher in the FM arm(71% [51 of 72 patients] v 51% [35 of 68 patients]; P = .01). However, with a median follow-up of 19 months (range, 9 to 37 months), no statistically significant difference was found among the various study arms in terms of both progression-free (PFS) and overall survival (OS). Conclusion: These results indicate that FM is superior to CHOP for front-line treatment of FL and that rituximab is an effective sequential treatment option. However, they also confirm that this superiority is unlikely to translate into either better PFS or OS.

Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.

ZINZANI, PIER LUIGI;SOVERINI, SIMONA;FATTORI, PIER PAOLO;ALINARI, LAPO;PILERI, STEFANO;TURA, SANTE;BACCARANI, MICHELE
2004

Abstract

Purpose: Promising new therapeutic options for follicular lymphoma (FL) include fludarabine plus mitoxantrone (FM) and the mouse/human anti-CD20 antibody, rituximab. We performed a randomized comparative trial of FM with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) front-line chemotherapy with and without sequential rituximab. Patients and Methods: All previously untreated CD20+ FL patients presenting in 15 Italian cooperative institutions from October 1999 were randomly allocated to FM or CHOP. Following clinical or molecular restaging, patients in complete remission (CR) with bcl-2/lgH negativity (CR-) received no further treatment; those in CR with bcl-2/lgH positivity (CR+) received rituximab, as did those in partial remission (PR) with bcl-2/lgH negativity (PR-) or positivity (PR+); nonresponders (NR subgroup) were off study. Results: After chemotherapy, the FM arm achieved higher rates of CR (68% [49 of 72 patients] v 42% [29 of 68 patients]; P = .003) and CR- (39% [28 of 72 patients] v 13 of 68 patients [19%]; P = .001). Rituximab elicited CR - in 55 of 95 treated patients (58%). The final CR- rate was higher in the FM arm(71% [51 of 72 patients] v 51% [35 of 68 patients]; P = .01). However, with a median follow-up of 19 months (range, 9 to 37 months), no statistically significant difference was found among the various study arms in terms of both progression-free (PFS) and overall survival (OS). Conclusion: These results indicate that FM is superior to CHOP for front-line treatment of FL and that rituximab is an effective sequential treatment option. However, they also confirm that this superiority is unlikely to translate into either better PFS or OS.
ZINZANI P.; PULSONI A; PERROTTI A; SOVERINI S; ZAJA F; DE RENZO A; STORTI S; LAUTA VM; GUARDIGNI L; GENTILINI P; TUCCI A; MOLINARI AL; GOBBI M; FALINI B; FATTORI PP; CICCONE F; ALINARI L; MARTELLI M; PILERI S; TURA S; BACCARANI M.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11585/2868
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 135
  • ???jsp.display-item.citation.isi??? 101
social impact